Stay updated on Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial
Sign up to get notified when there's something new on the Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial page.

Latest updates to the Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedThe study record for a Phase 3 deucravacitinib trial in psoriatic arthritis is available, with its design, eligibility requirements, outcome measures, locations, and supporting documents. The record also includes results and information about sharing anonymized participant data.SummaryDifference100%

- Check18 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide NIH notice appears above the ClinicalTrials.gov navigation, linking to transition updates and describing a change in terminology from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check33 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check61 days agoChange DetectedUpdated page to Revision: v3.7.0. Sponsor branding and links to study documents, IPD sharing information, and related resources were removed from the study record.SummaryDifference19%

Stay in the know with updates to Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Deucravacitinib in Active Psoriatic Arthritis: Clinical Trial page.